Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Tune Therapeutics, a Seattle-based biotech startup, has successfully raised over $175 million in a Series B financing round to advance its epigenome editing programs. This funding comes at a pivotal time as the company prepares for human testing of its epigenetic editing technologies in 2025. The financing will support clinical research aimed at developing therapies for chronic diseases, including hepatitis B. Investors in this round include Hevolution, highlighting the growing interest in epigenetic therapies as the healthcare industry converges in San Francisco for the JPMorgan Healthcare Conference.
.@vitarnabio's ongoing $1M fundraise is powering their mRNA longevity gene therapy into animal studies๐งฌ Past funding led to 15 potential drug candidates, with two showing promise in correcting nonsense mutations in cells. Join us๐ https://t.co/AEwAXGLbEl https://t.co/wiPdRKwmmA
Tune dials-in $175m to advance #epigenetic editing therapies @hevolution_f joins investors backing biotech that aims to harness the power of the epigenome to treat chronic diseases and improve #healthspan. @tunetx_news #longevity #investment #biotech https://t.co/k8zVFalDRd https://t.co/6I4LD1HbGl
Tune raises $175M for hepatitis B medicine, epigenetic research https://t.co/iV92hB6FP5 by @gwendolynawu
